What Clinical Trials Show In large obesity trials: Average weight loss is ~15% of starting body weight with semaglutide 2.4 mg Average weight loss is ~2022% of starting body weight with tirzepatide 15 mg The majority of weight loss occurs within the first year of treatment Plateaus are common after significant weight reduction Some people lose more, some less but a flattening of the weight-loss curve is expected , especially after meaningful progress has already occurred
Small bubbles from drawing doses are normal and resolve quickly
This led to its approval as a weight loss medication by the United States Food and Drug Administration (FDA)
So, the theory goes, Novo Nordisk let its patent lapse early to avoid the potential of more aggressive oversight from the review board, even if it meant having to contend with generics years earlier
In many cases, it will involve diet, exercise, and prescription weight loss medication like Semaglutide.
But knowing what to expect and how to respond makes the process significantly smoother